Table D13. Medication adherence outcomes 5

| Author, YearTrial Name | Medication Adherence Outcome 5 | Description of Timing of Measurement of Adherence Outcome 5 | Data Source | N | Results |
| --- | --- | --- | --- | --- | --- |
| Hoffman et al., 200318NA | Percent adherence using HEDIS guidelines, at 6 months | Measured once at 6 months; adherence defined as a total of 51 gap days since beginning treatment (days 1-180) | PRD | G1: 4889G2: 4665 | G1: 31.5G2: 29.495% CI, NRp: < 0.05 |
| Katon et al., 199625NA | A dosage of antidepressant medication for at least 90 days at or above lowest dosage recommended by AHCPR guidelines | NR | PRD | G1: 76G2: NS | Major Depression Group, for at least 30 days (% adherent)G1: 62.1%G2: 54.6%p=.55Minor Depression Group, for at least 30 days (% adherent)G1: 69.6%G2: 39.5%p=0.08 |
| Montori et al., 201135NA | Started bisphosphonates | Measured at baseline | PRD | G1: 52G2: 48 | TotalG1: 44%G2: 40%95% CI, NRp: NR<10% Risk CategoryG1: 50%G2: 25%95% CI, NRp: NR10-30% Risk CategoryG1: 45%G2: 45%95% CI, NRp: NR>30% Risk CategoryG1: 40% G2: 33%95% CI, NRp: NR |
| Murray et al., 200736NA | Refill adherence: Medication possession ratio (meds received relative to meds prescribed) | Results calculated for 1 yr, incorporating the 9 month intervention and 3 month post-intervention period; Presume that since refills were every 2 months, there were 6 measurements every 2 months | PRD | G1: NRG2: NR | G1: 109.4%G2: 105.2%95% CI, NRDifference: 4.2%p: 0.007 |
| Pyne et al., 201141HIV Translating Initiatives for Depression Into Effective Solutions (HITIDES) | Antidepressant prescription rates (of providers) at 6 months | Not clear whether self-report or other method. 3 measurements taken: baseline, 6-month and 12-months. | Other | G1: 72/108 (66.7) G2: 78/115 (67.8) | G1: 72/108 (66.7) G2: 78/115 (67.8)OR: 0.89 (0.49 to 1.78); adjusted OR; 0.89 (0.46 to 1.74) |
| Rich et al., 199642NA | Number of patients with >90% medication compliance (unclear which method used to calculate) | 30 days +/- 2 days after discharge; 1 time; NA | Pill count | G1: 80G2: 76 | G1: 45G2: 2695% CI, NR p: 0.032 |
| Rudd et al., 200445NA | Proportion of medications taken correctly among those on a >=2 times-daily dosing regimen | 1 day; daily ; 6 months | MEMS | NR | G1: 69% (34%)G2: 49% (41%)95% CI, NRp: NR, not significant per text |
| Stacy et al., 200956NA | 6 month point prevalence persistency (For those prescribed a lipid-lowering agent in the 7-12 month period prior to the index statin): subject being in possession of a statin at the end of the 180-day observation period | 6 months after baseline; 1 time; N/A | PRD | Overall N: 54SG1: NRSG2: NR | SG1: 66.7%SG2: 37.0%95% CI, NRp: <0.05 |
| Vivian et al., 200258NA | Compliance survey at 6 months: If answered yes to being away from home overnight in last 3 months, did you forget to take your medication when you were away from home overnight?, % who answered sometimes (2-3 times/wk) and always (>3 times/wk) | varied b/t groups; compliance measured in G1 at monthly visits, only measured at baseline and study end for G2 | Self-report | G1: 26G2: 27 | G1: 15%G2: 10%95% CI, NRp: 1.00 |
| Wilson et al., 201065Better Outcomes of Asthma Treatment (BOAT) | Controller regimen anti-in?ammatory potency - acquisition of beclomethasone canister equivalents - year 2 | Measured as aggregate for entire year | PRD | G1: 204G2: 202G3: 204 | G1: 7.1G3: 4.6Group difference: 2.5 95% CI, 1.2 to 3.8p= 0.0002G1: 7.1G2: 5.8;Group difference: 1.4 95% CI, 0.04 to 2.7p: 0.04G2: 5.8G3: 4.6Group difference:1.195% CI, -0.18 to 2.4p: >.05 |